ArticleScience advances2024
Label-free, real-time monitoring of cytochrome C drug responses in microdissected tumor biopsies with a multi-well aptasensor platform.
Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Continuous Molecular Monitoring Using Electrochemical Aptamer-Based Sensors: Remaining Challenges for Long-Term In Vivo Deployment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Multimodal Multiorgan-on-a-Chip Platform for Probing Liver-Tumor Interactions and Advancing Prodrug Screening.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Closed-Loop Synergistic Nitric Oxide/Hydrogen Delivery with Feedback Control for Diabetic Wound Healing.Nano-micro letters · 2026Article
- Organoids glimpse: the nexus for diverse tumor heterogeneity.Frontiers in cell and developmental biology · 2026Review
- Real-time and label-free monitoring of monoclonal antibody secretion rates using a PC-TIR biosensor.Biosensors & bioelectronics · 2025Article
- Beyond genomics: 3D microtumor assays for rapid, clinically relevant functional drug testing.Oncogene · 2025Review
- Real-Time, Continuous Monitoring of Tissue Chips as an Emerging Opportunity for Biosensing.Sensors (Basel, Switzerland) · 2025Review
- Low-cost robotic manipulation of live microtissues for cancer drug testing.Science advances · 2025Article
- Hybrid-integrated devices for mimicking malignant brain tumors ("tumor-on-a-chip") forFrontiers in medicine · 2024Review
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
Functional assays on intact tumor biopsies can complement genomics-based approaches for precision oncology, drug testing, and organs-on-chips cancer disease models by capturing key therapeutic response determinants, such as tissue architecture, tumor heterogeneity, and the tumor microenvironment. Most of these assays rely on fluorescent labeling, a semiquantitative method best suited for single-time-point assays or labor-intensive immunostaining analysis. Here, we report integrated aptamer electrochemical sensors for on-chip, real-time monitoring of cytochrome C, a cell death indicator, from intact microdissected tissues with high affinity and specificity. The platform features a multi-well sensor layout and a multiplexed electronic setup. The aptasensors measure increases in cytochrome C in the supernatant of mouse or human microdissected tumors after exposure to various drug treatments. Because of the sensor's high affinity, it primarily tracks rising concentrations of cytochrome C, capturing dynamic changes during apoptosis. This approach could help develop more advanced cancer disease models and apply to other complex in vitro disease models, such as organs-on-chips and organoids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.